Correlation Between Mineralys Therapeutics and Vaxcyte

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics and Vaxcyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics and Vaxcyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics Common and Vaxcyte, you can compare the effects of market volatilities on Mineralys Therapeutics and Vaxcyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics with a short position of Vaxcyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics and Vaxcyte.

Diversification Opportunities for Mineralys Therapeutics and Vaxcyte

0.46
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Mineralys and Vaxcyte is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics Common and Vaxcyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vaxcyte and Mineralys Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics Common are associated (or correlated) with Vaxcyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vaxcyte has no effect on the direction of Mineralys Therapeutics i.e., Mineralys Therapeutics and Vaxcyte go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics and Vaxcyte

Given the investment horizon of 90 days Mineralys Therapeutics Common is expected to under-perform the Vaxcyte. But the stock apears to be less risky and, when comparing its historical volatility, Mineralys Therapeutics Common is 1.19 times less risky than Vaxcyte. The stock trades about -0.16 of its potential returns per unit of risk. The Vaxcyte is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  6,557  in Vaxcyte on March 10, 2024 and sell it today you would earn a total of  694.00  from holding Vaxcyte or generate 10.58% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Mineralys Therapeutics Common  vs.  Vaxcyte

 Performance 
       Timeline  
Mineralys Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mineralys Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.
Vaxcyte 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxcyte are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Vaxcyte is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Mineralys Therapeutics and Vaxcyte Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mineralys Therapeutics and Vaxcyte

The main advantage of trading using opposite Mineralys Therapeutics and Vaxcyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics position performs unexpectedly, Vaxcyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcyte will offset losses from the drop in Vaxcyte's long position.
The idea behind Mineralys Therapeutics Common and Vaxcyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation